COVID-19 and sickle cell disease
Laurel A. Menapace and Swee Lay Thein
Sickle Cell Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
E-mail: SWEE LAY THEIN - sl.thein@nih.gov
doi:10.3324/haematol.2020.255598

The pandemic has posed unique challenges to healthcare providers involved in the care of individuals with chronic conditions, balancing maintenance of necessary care with appropriate precautions to reduce their exposure to infection. Patients with sickle cell disease (SCD) present multiple challenges due to the complexity of their condition, disease-related comorbidities, and need for frequent medical interventions. To date, there has been a paucity of published data on how COVID-19 may impact morbidity and mortality in SCD patients.

In this edition of Haematologica, Charkravorty and colleagues report associated outcomes in 10 UK patients infected with SARS-CoV-2. All patients had hemoglobin (Hb) SS disease with pre-existing co-morbidities, despite this nine patients made a full recovery without receiving COVID-19 directed therapies. Five patients were hospitalized and treated supportively; two patients who had a cough and hypoxia received early preventive simple transfusions; five patients were managed at home via close telephone contact. Of the 10 patients, seven were female (median age of 37 years); two received hydroxyurea therapy and seven received regular blood transfusions (four exchange and three simple transfusions). Given that COVID-19 is an acute infectious disease, most experts anticipated that SARS-CoV-2 infection would trigger acute chest syndrome (ACS) yet only one patient who died in this series had significant respiratory complications. The patient who died was a 54-year-old female with severe asthma, alloimmunization, and a history of delayed hemolytic transfusion reactions which prevented routine transfusion. The patient had lymphopenia, thrombocytopenia and elevated C-reactive protein (CRP), which have been identified as poor prognostic markers in COVID-19 patients. The authors acknowledge that the demographic and treatment characteristics of this cohort may have influenced the observed outcomes.

This edition also includes a report of 195 cases of suspected or confirmed SARS-CoV-2 infection as captured by 10 regional centers in a real time survey over a 4-week period in the UK. Patients with SCD represented the majority of cases (n=166, 85.1%) with Hb SS disease as the most common genotype (Hb SS 64.1%; Hb SC 15.4%; other genotypes 5.6%) followed by thalassemia (n=26, 13.5%) and rare inherited anemias (n=3, 1.5%). While the incidence of ACS in the SCD cohort was not specified, red cell exchange was performed in 46 patients during the course of infection. A total of eight SCD patients required mechanical ventilatory support in the setting of respiratory failure; 11 of 13 deaths attributed to COVID-19 occurred in patients with SCD. A subset analysis of 76 hospitalized SCD patients with PCR confirmed SARS-CoV-2 showed that the patient age was significantly associated with mortality, with the most deaths occurring in those aged 50 and older (n=4). The authors noted that three patients aged 20-39 years in the subset succumbed to COVID-19 although details regarding the comorbid medical conditions were not provided. Unexpectedly, mortality was higher in females and was not associated with severity of disease but observed differences were insignificant. The cases reported to date represent 1.2% of the estimated 13,655 individuals with SCD per registry data in England. There was a low incidence of infection in children (n=20) and there were no pediatric deaths. Definitive conclusions regarding COVID-19 mortality rates in SCD cannot be drawn given inherent ascertainment bias and missing data in the survey.

The mild clinical course of COVID-19 in the King’s College Hospital SCD patients was similarly encountered in a case series of four patients from Chicago, all of whom presented with acute pain. Of the four patients, three received the usual supportive care but one patient, a 32-year-old male with Hb SS, developed ACS requiring intubation and exchange transfusion.

Two other centers reported COVID-19 pneumonia causing ACS in SCD patients. A 21-year-old male with Hb S/ß thalassemia on hydroxyurea therapy presented with acute chronic left hip pain and subsequently developed a cough with progressive hypoxia and evidence of new pulmonary infiltrates during his hospital course. SARS-CoV-2 PCR testing was positive during the second week of admission. In addition to antibiotic therapy, the patient was initiated...
on hydroxychloroquine and received exchange transfusion which reduced the Hb S level from 87.1% to 18.1%. He made a full recovery and was discharged after 16 days in the hospital.

The Amsterdam University Medical Centers reported two Hb SS patients who presented with typical acute sickle pain with no accompanying flu-like symptoms. A 24-year-old male presented with acute thoracic pain in the absence of fever or dyspnea; throat and nose swabs were negative for SARS-CoV-2. Computed tomography (CT) imaging revealed bilateral pulmonary infiltrates and the patient received the presumptive diagnosis of a vaso-occlusive crisis (VOC) complicated by ACS. He received antibiotic therapy and was discharged home only to return 24 hours later with increasing pain, dyspnea, and fever. Repeat chest imaging demonstrated progression of infiltrates but radiologic findings were not consistent with COVID-19 pneumonia. A repeat PCR performed on a sputum sample was positive for SARS-CoV-2. The patient received appropriate supportive treatment and had an uneventful recovery. Patient 2, a 20-year-old female presented with an acute pain crisis. She developed transient hypoxia and subsequent SARS-CoV-2 testing was positive. Although CT imaging of the chest did not demonstrate pulmonary abnormalities, she was hospitalized for pain management and never developed respiratory symptoms or fever. We have not been informed if these patients were on hydroxyurea or regular blood transfusion programs.

Although anecdotal, a few important themes emerge from these cases – that COVID-19 might trigger a VOC without the accompanying respiratory manifestations of COVID-19, that ACS is not as common a complication as feared, and that fever was notably absent at presentation in some SCD patients, a feature also noted among 5,700 patients admitted with COVID-19 in New York City.

Are patients with SCD at greater risk for serious illness secondary to COVID-19?

Data from non-SCD cohorts have demonstrated that advanced age and the presence of medical co-morbidities including cardiovascular disease, hypertension, diabetes mellitus, and pre-existing lung disease place individuals at higher risk for developing severe complications as a result of COVID-19, including catastrophic acute hypoxic respiratory failure. Critically ill patients can develop a cytokine storm, progressive endothelial activation with associated risk of micro- and macrothrombi, and disseminated intravascular coagulation (DIC) resulting in multi-organ failure. Marked elevations in D-dimer and prothrombin with a reduction in fibrinogen levels herald a worse prognosis and heightened risk of death in COVID-19 patients.

Patients with SCD, in particular older adults, often have multiple comorbidities with progressive renal insufficiency, hypertension, and chronic lung disease including pulmonary hypertension. Viral infection can trigger acute vaso-occlusive crises, including ACS which is associated with high mortality rates. In this setting of multi-organ dysfunction, in particular chronic lung damage, COVID-19 could easily trigger ACS and multi-organ failure.
Underlying endothelial dysfunction and abnormal expression of procoagulants such as tissue factor could also place SCD patients at a greater risk of thromboinflammation and thrombotic events if infected with SARS-CoV-2.14 Data from the US have shown higher rates of symptomatic infection requiring hospitalization and death in patients of African American and Hispanic ethnicity highlighting racial health disparities which impact the SCD community.15

Importantly, COVID-19 directed therapies such as antimalarial agents (hydroxychloroquine or chloroquine) may confer additional risks and must be considered carefully given conflicting data regarding effectiveness.16,17 One well-known adverse effect is methemoglobinemia, particularly in individuals with concomitant G6PD deficiency. Over a 4-week period in a single health system, eight COVID-19 patients who were treated with hydroxychloroquine developed methemoglobinemia which was significant in three patients necessitating treatment with methylene blue.18 Of note, 1 of the 3 patients who developed acute hemolysis was found to have a new diagnosis of G6PD deficiency. In this respect, hydroxychloroquine treatment presents additional risks in SCD patients in whom concomitant G6PD deficiency is not uncommon; in addition to other adverse cardiac effects including QT prolongation and ventricular arrhythmias.

Strategies to optimize management of SCD patients during the COVID-19 pandemic

Hematologists caring for SCD patients have transitioned to telemedicine to reduce unnecessary exposure to SARS-CoV-2 in healthcare settings. Given asymptomatic transmission, healthcare providers should be vigilant in educating patients regarding social isolation practices in their geographic area, hand hygiene, and precautions when in public settings. Patients should be encouraged to be adherent to disease modifying therapies such as hydroxyurea to reduce the frequency of VOC episodes requiring medical attention. Laboratory monitoring for hydroxyurea and iron chelating drugs may need to be done less frequently, and when feasible, medications should be mailed or delivered to the home. Routine visits to the clinic or hospital should be avoided unless phone triage indicates acute symptoms requiring medical evaluation. Some individuals may be able to manage uncomplicated pain crises at home with optimization of oral opioid regimens and close supervision from healthcare providers. Clinical teams should develop dedicated care pathways including phone screening to assess for COVID-19 symptoms prior to a scheduled visit, clinical screening before physical entrance including temperature measurement and symptom assessment, physical distancing in waiting areas, as well as treatment in COVID-19 free clinical areas or isolation rooms. Cross-coverage of providers in the inpatient and outpatient setting should be limited and rotating clinical team schedules are encouraged to reduce the asymptomatic spread of SARS-CoV-2.

Strategies to decrease blood utilization in the setting of blood shortages

In the pandemic setting, there is a risk of severe blood shortages due not only to a decrease in donor participation but a decrease in personnel to collect and process blood. Regular blood transfusion is standard therapy for patients who have suffered an overt stroke as this offers the greatest protection from recurrence of further strokes; such patients should continue to receive transfusions in the presence of adequate blood supply. Patients with abnormal transcranial doppler (TCD) measurements may be eligible for transition to hydroxyurea therapy as per TWiCH trial criteria for the prevention of a primary stroke.19,20 In order to preempt the possibility of blood supply interruption, it has been suggested that all children on blood transfusion therapy for primary and secondary stroke prevention should be started on low-dose hydroxyurea (HU) therapy (fixed 10 mg/kg/day).21 Dose escalation of HU requires frequent laboratory monitoring of peripheral blood counts which may be undesirable in areas with high rates of community spread. DeBaun emphasizes that there can only be advantages in initiating low-dose HU therapy for patients on transfusion programs for stroke prevention – low-dose HU has a minimal risk of myelosuppression, starting low-dose HU will decrease the lag time for clinical benefits if transfusions are suspended, and low-dose HU confers additional clinical benefits, such as reducing the frequency of VOC and ACS. Another approach to conserve blood during the COVID-19 pandemic is to dose-escalate hydroxyurea as this may reduce transfusion needs in SCD patients with a history of stroke.22 Outside stroke prevention, transfusion hemoglobin thresholds may be relaxed in patients without cardiopulmonary comorbidities in the absence of acute symptoms or organ dysfunction secondary to anemia. Simple blood transfusions may be substituted for exchange regimens and Hb S goals could also be relaxed (e.g., Hb S of 40% instead of 30%).23 Routine pre-transfusion laboratory work should be performed on the day of a scheduled transfusion to reduce unnecessary exposure to healthcare settings. Advanced planning for patients with extensive alloimmunization is necessary given that matched blood products may be difficult to source; transfusion of the least incompatible blood product with rituximab prophylaxis may be considered in emergency situations due to life-threatening anemia.24 A triage of managing SCD patients in the COVID-19 pandemic setting is proposed in Figure 1.

Conclusions

Many unknown factors remain when considering the impact of COVID-19 in SCD patients. From published case reports, it is not clear if SCD increases the risk of SARS-CoV-2 infection. What is clear, is that fever is not always a feature, acute pain is a common presentation and COVID-19 can induce ACS but patients can recover fully with adequate supportive care. Importantly, lifesaving measures including mechanical ventilation should not be withheld from patients with SCD in the midst of this pandemic.

References

1. Fauci AS, Lane HC, Redfield RR. Covid-19 - Navigating the uncharted. N Engl J Med. 2020;382(13):1268-1269.
2. Organization WH. Coronavirus disease (COVID-19) situation summary. 2020 [cited; Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports].
A CD205-directed antibody drug conjugate – lymphoma precision oncology or sophisticated chemotherapy?

Damian T. Rieke1,2 and Ulrich Keller1,3

1 Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, 12203 Berlin; 2Berlin Institute of Health (BIH), 10478 Berlin and 3Max-Delbrück-Center for Molecular Medicine, 13092 Berlin, Germany

E-mail: ULRICH KELLER - ulrich.keller@charite.de

doi:10.3324/haematol.2020.261073

Precision oncology is expected to improve outcome of patients with malignant diseases by taking into account individual variability. This approach is strictly linked to the availability of a targeted treatment the efficacy of which depends on the presence of a molecular alteration, i.e., a predictive biomarker. This concept has been shown to be highly successful in well-defined subgroups of patients and has led to the histology-agnostic approval of drugs in solid tumors. Biomarker-stratified treatment has become first-line treatment in several solid tumors, such as non-small cell lung cancer. In many hematopoietic malignancies, including B-cell lymphomas, comparably higher cure rates and more treatment options have led to a more prognosis-oriented stratification of treatment. Here, prognostic biomarkers help to adjust treatment intensity to a cohort risk assessment. Together with improved prognostication of patients, a more refined diagnosis also helps with better treatment allocation.

Therefore, diagnostic biomarkers will help with the identification of defined disease subgroups. This might also correspond to differential outcome and/or response to treatment, and can therefore overlap with predictive and/or prognostic markers. However, despite numerous advances in the understanding of cancer heterogeneity, not all diagnostic or prognostic stratifications will ultimately impact treatment and a number of patients will eventually have disease recurrence or progression. Therefore, the identification of novel treatment strategies is urgently required. The development of additional predictive biomarkers and corresponding drugs promises to improve outcome and limit toxicity. This advancement of precision oncology can be achieved in at least two ways: (i) the identification of the right treatment for given patients (as often tried in umbrella- or unstratified precision oncology trials); or (ii) the identification of the right patient for a given treatment (as...